Breaking News Instant updates and real-time market news.

SNAP

Snap

$13.52

0.59 (4.56%)

, VRX

Valeant

$15.13

-0.32 (-2.07%)

07:35
08/07/17
08/07
07:35
08/07/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Snap Inc. (SNAP), Valeant (VRX), Gilead (GILD), Goldman Sachs (GS), Comcast (CMCSA), Goldcorp (GG), Energy Transfer Equity (ETE), CF Industries (CF), Viacom (VIAB), and Thor Industries (THO).

SNAP

Snap

$13.52

0.59 (4.56%)

VRX

Valeant

$15.13

-0.32 (-2.07%)

GILD

Gilead

$73.16

-1.21 (-1.63%)

GS

Goldman Sachs

$229.79

5.8 (2.59%)

CMCSA

Comcast

$39.60

-0.1 (-0.25%)

GG

Goldcorp

$12.56

-0.25 (-1.95%)

ETE

Energy Transfer Equity

$17.33

0.02 (0.12%)

CF

CF Industries

$32.21

1.5 (4.88%)

VIAB

Viacom

$30.22

-4.85 (-13.83%)

THO

Thor Industries

$104.68

2.22 (2.17%)

  • 08

    Aug

  • 08

    Aug

  • 10

    Aug

  • 24

    Aug

  • 13

    Sep

  • 17

    Oct

SNAP Snap
$13.52

0.59 (4.56%)

07/27/17
NEED
07/27/17
NO CHANGE
Target $185
NEED
Buy
Facebook 'strong over-delivery' a negative for Snap, says Needham
Needham analyst Laura Martin believes Facebook's (FB) "strong over-delivery" of Q2 earnings is negative for Snap (SNAP) because Instagram Stories hit 250M DAU's in Q2, well above Snap's 166M DAU's in Q1. The analyst reiterates a Buy rating and $185 price target on Facebook's shares.
07/25/17
07/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Sell from Hold at Deutsche Bank with analyst Paul Trussell saying a "difficult and promotional selling environment along with segmentation challenges" weaken his confidence in the company's near-term results. 2. Snap (SNAP) downgraded to Neutral from Buy with analyst Kevin Rottinghaus citing monetization concerns and increasing pressure from Facebook (FB) competition. 3. Cytori Therapeutics (CYTX) downgraded to Neutral from Buy at B. Riley with analyst Andrew D'Silva citing the STAR trial results, which missed both primary and secondary endpoints. The analyst cut his price target for the shares to 50c from $2.30. 4. lululemon (LULU) downgraded to Hold from Buy at Stifel with analyst Jim Duffy citing valuation. 5. Power Integrations (POWI) downgraded to Hold from Buy at Deutsche Bank with analyst Ross Seymore saying he has no incremental knowledge to support or refute market speculation regarding a potential design win in the upcoming Apple (AAPL) iPhone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
DBAB
08/07/17
NO CHANGE
Target $20
DBAB
Buy
Snap shares should rebound in second half of year, says Deutsche Bank
Snap shares offer a "compelling" risk/reward profile at current levels, Deutsche Bank analyst Lloyd Walmsley tells investors in a research note titled "Remember, It's a 2H Story." The analyst sees "innovation thriving" at Snap across the app, advertising product and ad technology. Intra quarter ad checks have started to pick up with industry contacts noting brand advertisers are increasingly of the view that Snap offers compelling view rates and view-to-completion rates, Walmsley writes. He expects continued product innovation to drive growth in daily active users and engagement over time. Snap shares should rebound in the second half of 2017 as it's "inflection comes into focus," Walmsley argues. He lowered his price target for the shares to $20 from $23 and keeps a Buy rating on the name. The analyst points out that his new lowered price target still reflects 51% upside from current share levels. Snap closed Friday up 60c to $13.52.
07/31/17
OTRG
07/31/17
DOWNGRADE
OTRG
Mixed
Snap downgraded to Mixed from Positive at OTR Global
VRX Valeant
$15.13

-0.32 (-2.07%)

07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/17/17
WELS
07/17/17
NO CHANGE
WELS
Underperform
Wells says Valeant selling Obagi for less than half of price paid in 2013
After Valeant announced it has agreed to sell its Obagi Medical Products business for $190M in cash, Wells Fargo analyst David Maris noted that this sale price is less than half of the $437M that the company paid to acquire Obagi in April 2013. While Valeant continues to make progress toward its asset sales and debt reduction targets, Maris does not believe that its recent divestitures have had a significant deleveraging impact. He keeps an Underperform rating on Valeant shares.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
GILD Gilead
$73.16

-1.21 (-1.63%)

07/14/17
LEER
07/14/17
NO CHANGE
LEER
Acquisition of Incyte would make sense for Gilead, says Leerink
Leerink analyst Geoffrey Porges, who noted he has "written extensively about the imperative for Gilead to diversify their portfolio and secure additional pipeline programs," said in a new note to investors that he believes an acquisition of Incyte (INCY) would make sense for Gilead (GILD). At a "reasonable acquisition premium," Gilead could pay $173-$187 per share for Incyte and its earnings would be diluted through 2018, but thereafter would be increased by such a deal, estimated Porges. The analyst, who concluded that Incyte presents a high-risk/high-reward option for Gilead, keeps a Market perform rating on Gilead shares.
07/27/17
COWN
07/27/17
NO CHANGE
Target $90
COWN
Outperform
Gilead results a 'welcome' beat and raise, says Cowen
Cowen analyst Phil Nadeau called the Gilead results a "welcome beat and raise" for what is a very cheap name. The analyst said it may be too early to confidently say the business has stabilized, but his discounted free cash flow analysis suggests the shares remain undervalued. Nadeau reiterated his Outperform rating and $90 price target on Gilead shares.
07/27/17
JPMS
07/27/17
NO CHANGE
Target $85
JPMS
Overweight
Gilead price target raised to $85 from $80 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for Gilead Sciences to $85 saying the Q2 beat-and-raise quarter is "encouraging." The HCV franchise is still in decline, but the "resiliency this quarter helps further fuel ample cash generation," Kasimov tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
07/13/17
BARD
07/13/17
NO CHANGE
Target $87
BARD
Outperform
Baird likes Gilead heading into Q2 earnings
Baird analyst Brian Skorney said he likes Gilead heading into Q2 earnings. The analyst said Hep-C sales should beat estimates and predicts its sales decline should be approaching a plateau, which would result in upside to the shares. He said the operating results could provide much needed stability, which should also result in upside. Skorney maintained his Outperform rating and $87 price target on Gilead shares.
GS Goldman Sachs
$229.79

5.8 (2.59%)

07/19/17
OPCO
07/19/17
NO CHANGE
Target $256
OPCO
Outperform
Goldman Sachs price target raised to $256 from $251 at Oppenheimer
Oppenheimer analyst Chris Kotowski raised his price target for Goldman Sachs to $256 from $251 as he still thinks there is a "reasonable probability" of a FICC rebound once long-term rates go up and thinks the market is awarding a near zero value to this. The analyst reiterates an Outperform rating on the shares.
07/19/17
07/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMC Entertainment (AMC) downgraded to Equal Weight from Overweight at Barclays with analyst Kannan Venkateshwar saying he sees increased risk after China indicated over the weekend that the government has blocked banks from funding AMC's parent, Chinese real estate conglomerate Dalian Wanda. 2. Chipotle (CMG) downgraded to Market Perform from Outperform at BMO Capital and Wells Fargo. 3. Goldman Sachs (GS) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Brian Kleinhanzl saying he sees a weakening revenue outlook following the investment bank's second quarter results. 4. PayPal (PYPL) downgraded to Hold from Buy at SunTrust with analyst Andrew Jeffrey citing valuation, "long-term competitive risk, and uncertain Venmo monetization." 5. First Solar (FSLR) downgraded to Hold from Buy at Standpoint Research with analyst Ronnie Moas saying the stock is fairly valued after jumping 70% over the past three months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
UBSW
07/24/17
DOWNGRADE
Target $230
UBSW
Neutral
Goldman Sachs downgraded to Neutral from Buy at UBS
UBS analyst Brennan Hawken downgraded Goldman Sachs (GS) to Neutral and cut his price target for the shares to $230 from $255. The bank closed Friday down $2.12 to $220.18. The market seems to be pricing in an inflection in Goldman's trading revenue despite the recent weakness, suggesting a recovery is needed to justify 2018 consensus estimates, Hawken tells investors in a research note. The analyst sees better opportunities for investors, such as Morgan Stanley (MS), as he has "limited confidence" in a revenue recovery at Goldman.
07/24/17
07/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the market seems to be pricing in an inflection in Goldman's trading revenue despite the recent weakness, suggesting a recovery is needed to justify 2018 consensus estimates. 2. Constellation Brands (STZ) downgraded to Neutral from Conviction Buy at Goldman Sachs. 3. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees further downside risk from weaker volumes and believes 2018 will be another year of volume decline and limited margin offset. 4. athenahealth (ATHN) downgraded to Underweight from Equal-Weight at First Analysis with analyst Frank Sparacino saying the valuation at current share levels is ahead of the underlying fundamentals in the short term. 5. PPG (PPG) was downgraded to Hold from Buy at SunTrust and to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMCSA Comcast
$39.60

-0.1 (-0.25%)

07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
08/03/17
GUGG
08/03/17
UPGRADE
GUGG
Buy
Comcast upgraded to Buy from Neutral at Guggenheim
Guggenheim analyst Michael Morris upgraded Comcast to Buy and raised its price target to $46 to reflect an attractive valuation, a combination of solid trends at Cable Communications and NBCU content momentum, and strong balance sheet. Morris expects reduced 2018 Cable programming cost growth, advertising momentum, and a strong film slate driving investor interest.
08/03/17
08/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comcast (CMCSA) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris citing an attractive valuation, a combination of solid trends at Cable Communications and NBCU content momentum, and strong balance sheet. 2. Caterpillar (CAT) upgraded to Neutral from Underweight at Atlantic Equities. 3. SodaStream (SODA) upgraded to Positive from Neutral at Susquehanna. 4. Walker & Dunlop (WD) upgraded to Outperform from Market Perform at JMP Securities with analyst Steven DeLaney saying investors may be overly focusing on quarterly results and the reduction in the company's gain on sale margin guidance for the second half of the year. 5. Oshkosh (OSK) upgraded to Neutral from Underperform at BofA/Merrill with analyst Ross Gilardi citing better than expected third quarter results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/17
SBSH
07/26/17
NO CHANGE
SBSH
Comcast should acquire Verizon for four reasons, says Citi
Citi analyst Jason Bazinet says Comcast (CMCSA) should acquire Verizon (VZ) for four reasons. Wireless would allow Comcast to extend Internet connectivity beyond the home, the deal would allow the company to push fiber deeper into neighborhoods, Verizon is apt to be the second biggest beneficiary of wireless consolidation, and Comcast could see upside if the tax code changes, Bazinet tells investors in a research note titled "Stars Are Aligning for Comcast + Verizon." The analyst sees the timing for a deal as right given Comcast's history of "trying to acquire assets that have fallen on difficult times" and the potential for a more amendable regulatory landscape under President Trump. Further, 2017 is the first year where Comcast's market capitalization exceeds Verizon's, the analyst adds. He estimates the pro forma combined company would generate $2.1B of annual synergies. Assuming a 20% premium for Verizon's equity, paid via 75% equity and 25% cash, Bazinet estimates Comcast shares would rise to $41. The stock closed yesterday up 28c to $39.75. Bazinet thinks Dish (DISH) could be the biggest loser should Comcast acquire Verizon, and he double downgraded the shares this morning to Sell from Buy.
GG Goldcorp
$12.56

-0.25 (-1.95%)

07/24/17
NATB
07/24/17
DOWNGRADE
NATB
Sector Perform
Goldcorp downgraded to Sector Perform from Outperform at National Bank
07/12/17
MACQ
07/12/17
UPGRADE
MACQ
Outperform
Goldcorp upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Michael Siperco upgraded Goldcorp to Outperform citing valuation and expectations for better second half results.
03/16/17
RBCM
03/16/17
UPGRADE
RBCM
Sector Perform
Goldcorp upgraded on vaulation, operational progress at RBC Capital
As noted earlier, RBC Capital upgraded Goldcorp to Sector Perform from Underperform. Analyst Stephen Walker upgraded the stock based on valuation and the progress the company has made with a number of its major projects. Target to $17 from $15.
03/29/17
RODM
03/29/17
DOWNGRADE
Target $1.75
RODM
Neutral
Exeter Resource downgraded to Neutral from Buy at Rodman & Renshaw
Rodman & Renshaw analyst Heiko Ihle downgraded Exeter Resource (XRA citing the takeover by Goldcorp (GG). The analyst believes additional bidders are unlikely. He has a $1.75 price target for the shares.
ETE Energy Transfer Equity
$17.33

0.02 (0.12%)

05/10/17
BERN
05/10/17
UPGRADE
BERN
Outperform
Energy Transfer Equity upgraded to Outperform from Market Perform at Bernstein
05/10/17
BERN
05/10/17
UPGRADE
BERN
Outperform
Energy Transfer Equity, Energy Transfer Partners upgraded at Bernstein
As noted earlier, Bernstein upgraded Energy Transfer Equity (ETE) and Energy Transfer Partners (ETP) to Outperform from Market Perform. Analyst Jean Ann Salisbury says that the companies are "arguably levered" to three growth areas: Permian, Marcelllus, and ethane volumes. The analyst adds that several "very positive developments" for the companies have occurred since January: the DAPL project proceeded and its "finish line is in sight; progress was made with the Rover project; the DEP approved Mariner East 2; and 73 rigs were added in the Permian, while oil production there rose meaningfully. Target $23 for Energy Transfer Equity and $30 for Energy Transfer Partners.
05/12/17
WOLF
05/12/17
INITIATION
Target $20
WOLF
Peer Perform
Energy Transfer Equity initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated Energy Transfer Equity with a Peer Perform and a $20 price target.
07/13/17
STFL
07/13/17
INITIATION
STFL
Buy
Energy Transfer Equity initiated with a Buy at Stifel
Stifel analyst Selman Akyol started coverage of Energy Transfer Equity with a $20 price target and a Buy rating. The analyst predicts that the company's distributable cash flow will jump more than 70% in 2018, and he says that the owner of the Energy Transfer family of companies is "predominately aligned" with Energy Transfer Equity.
CF CF Industries
$32.21

1.5 (4.88%)

06/06/17
CLVD
06/06/17
NO CHANGE
Target $23
CLVD
Neutral
CF Industries estimates lowered at Cleveland Research
Cleveland Research lowered its FY17 forecasts for CF Industries due to weaker ammonia, urea and UAN prices. The firm cut its price target on CF Industries to $23 from $25 and keeps a Neutral rating on the stock.
05/08/17
SBSH
05/08/17
UPGRADE
Target $34
SBSH
Buy
CF Industries upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded CF Industries to Buy citing a favorable risk/reward following the recent selloff in the shares. The analyst has a $34 price target for the stock.
07/26/17
07/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Market Perform from Outperform at BMO Capital. 2. Zoetis (ZTS) downgraded to Hold from Buy at Deutsche Bank with analyst Gregg Gilbert saying the risk/reward is more balanced with the shares up 18% year-to-date. 3. CF Industries (CF) downgraded to Neutral from Outperform at Credit Suisse with analyst Christopher Parkinson citing the recent rally in shares. 4. Eli Lilly (LLY) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez saying that the regulatory update for Olumiant removes upside optionality in rheumatoid arthritis and possibly other indications given concerns over thrombosis risk. 5. Wynn Resorts (WYNN) was downgraded to Hold from Buy at Union Gaming and to Market Perform from Outperform at Telsey Advisory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/17
FBCO
07/26/17
DOWNGRADE
Target $30
FBCO
Neutral
CF Industries downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Christopher Parkinson downgraded CF Industries to Neutral citing the recent rally in shares and trimmed its price target to $30 from $31.
VIAB Viacom
$30.22

-4.85 (-13.83%)

07/26/17
WELS
07/26/17
NO CHANGE
WELS
Scripps Networks could be acquired for $91-$95 per share, says Wells Fargo
After the Wall Street Journal reported that Discovery (DISCA) and Viacom (VIAB) are interested in buying Scripps' (SNI) assets, Wells Fargo estimates that Scripps could be acquired for $91-$95 per share. The firm believes that the acquirer or acquirers could realize a total of about $175M of non-programming expense synergies. It keeps a Market Perform rating on Scripps.
07/17/17
JPMS
07/17/17
NO CHANGE
JPMS
Overweight
Viacom shares offer 'great value' at current levels, says JPMorgan
JPMorgan analyst Alexia Quadrani says Viacom over the past few months experienced improving ratings across several of its key networks, which she believes supports a positive outlook for advertising improvement. Shares of Viacom present "great value at these levels," Quadrani tells investors in a research note. She reiterates an Overweight rating on the stock.
08/04/17
EVER
08/04/17
NO CHANGE
Target $48
EVER
Outperform
Evercore ISI would be a buyer of Viacom near-term weakness at Evercore ISI
Evercore ISI analyst Vijay Jayant would use weakness in Viacom share related to disappointing guidance as a buying opportunity. The analyst believes the company is heading int the right direction under new CEO Bob Bakish, and said there are some early signs that his restructuring plan is working. Jayant rates Viacom an Outperform with a $48 price target.
08/04/17
ATLE
08/04/17
DOWNGRADE
ATLE
Underweight
Viacom downgraded to Underweight from Neutral at Atlantic Equities
THO Thor Industries
$104.68

2.22 (2.17%)

02/08/17
02/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Buy from Neutral at BTIG with analyst Rich Greenfield citing his belief that Twitter's daily active user growth is accelerating, particularly in the U.S., following the presidential election. 2. UPS (UPS) upgraded to Buy from Hold at Aegis with analyst Jeffrey Kauffman citing valuation. 3. Emerson (EMR) upgraded to Neutral from Sell at UBS with analyst Shannon O'Callaghan citing better order trends and margin execution following the company's December quarter results. The analyst raised his price target for the shares to $64 from $51. 4. FMC Corporation (FMC) upgraded to Buy from Neutral at Longbow with analyst Dmitry Silversteyn saying that the company's Latin American agricultural operations appear to have stabilized, and as a result he thinks that its second half 2017 results will be strong. 5. Thor Industries (THO) upgraded to Outperform from Neutral at Baird with analyst Craig Kennison saying he sees Thor as a market leader and channel checks show dealers are optimistic and willing to restock inventory. He sees long-term upside to margins and likes the chance tax reform will boost consumer demand and corporate profits. Kennison raised his price target to $120 from $105 on Thor shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/17
BARD
02/08/17
UPGRADE
Target $120
BARD
Outperform
Thor Industries upgraded to Outperform at Baird
As reported previously, Baird analyst Craig Kennison upgraded Thor Industries to Outperform from Neutral. The analyst sees Thor as a market leader and channel checks show dealers are optimistic and willing to restock inventory. He sees long-term upside to margins and likes the chance tax reform will boost consumer demand and corporate profits. Kennison raised his price target to $120 from $105 on Thor shares.
07/06/17
STFL
07/06/17
INITIATION
Target $110
STFL
Hold
Thor Industries initiated with a Hold at Stifel
Stifel analyst Michael Baudendistel initiated Thor Industries with a Hold and a $110 price target given his belief 2019 earnings will be at or near peak levels and there are no clear catalysts to push shares higher.
04/20/17
RHCO
04/20/17
NO CHANGE
RHCO
Concerns about Thor Industries overdone, says SunTrust
SunTrust analyst Michael Swartz notes that Thor's stock has fallen about 20% since March. The analyst blames the decline on "softness" in its sector and on several concerns about the company. He says there is concern that "the industry has peaked," but he expects the sector to grow at a 4%-8% CAGR over the next four years. Swartz adds that concerns about its inventory growth are misplaced because the growth reflects the impact of positive trends, while the Q2 gross margin mix was caused by " product mix and labor inefficiencies" He agrees that the company could have difficulty growing its backlog, but he does not think this reflects a coming slowdown in its revenue growth. Swartz says that "many" of these concerns could be eliminated within six months, and he keeps a $125 price target and Buy rating on the stock.

TODAY'S FREE FLY STORIES

CRVS

Corvus Pharmaceuticals

$13.00

1.13 (9.52%)

20:37
08/23/17
08/23
20:37
08/23/17
20:37
Upgrade
Corvus Pharmaceuticals rating change at Credit Suisse »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$56.28

0.33 (0.59%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Upgrade
Portola Pharmaceuticals rating change at Credit Suisse »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 02

    Feb

TEVA

Teva

$16.49

-0.52 (-3.06%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Downgrade
Teva rating change at Credit Suisse »

Teva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 27

    Sep

LOW

Lowe's

$73.01

-2.81 (-3.71%)

20:33
08/23/17
08/23
20:33
08/23/17
20:33
Downgrade
Lowe's rating change at BMO Capital »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 21

    Nov

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

, DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

20:25
08/23/17
08/23
20:25
08/23/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

SJM

J.M. Smucker

$118.85

-1.01 (-0.84%)

TIF

Tiffany

$88.72

0.22 (0.25%)

TTC

Toro Company

$69.02

-1.76 (-2.49%)

SPLS

Staples

$10.18

-0.02 (-0.20%)

BURL

Burlington Stores

$84.95

-1.43 (-1.66%)

MIK

Michaels

$19.61

0.02 (0.10%)

SIG

Signet Jewelers

$51.89

-0.26 (-0.50%)

ANF

Abercrombie & Fitch

$9.61

0.46 (5.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 05

    Sep

  • 06

    Sep

  • 03

    Oct

  • 04

    Oct

HSY

Hershey

$107.44

0.34 (0.32%)

19:16
08/23/17
08/23
19:16
08/23/17
19:16
Hot Stocks
Hershey Company to acquire 1.5M common shares from Hershey Trust »

The Hershey Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSADY

MS&AD Insurance

$17.08

-0.085 (-0.50%)

19:07
08/23/17
08/23
19:07
08/23/17
19:07
Hot Stocks
MS&AD Insurance to acquire First Capital Insurance in $1.6B deal »

Fairfax Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$169.00

-1.07 (-0.63%)

18:46
08/23/17
08/23
18:46
08/23/17
18:46
Hot Stocks
Amgen: Lancet Oncology publishes survival analysis from KYPROLIS Phase 3 trial »

Amgen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

GE

General Electric

$24.39

-0.21 (-0.85%)

, ABB

ABB

$23.13

-0.01 (-0.04%)

18:39
08/23/17
08/23
18:39
08/23/17
18:39
Periodicals
GE resumes talks with ABB over industrial solutions deal, Reuters reports »

General Electric (GE) has…

GE

General Electric

$24.39

-0.21 (-0.85%)

ABB

ABB

$23.13

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

  • 02

    Oct

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

, AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

18:17
08/23/17
08/23
18:17
08/23/17
18:17
Periodicals
La-Z-Boy in talks with Amazon over youth shopper outreach, MarketWatch reports »

La-Z-Boy (LZB) is in…

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

VLKAY

Volkswagen

$30.67

0.19 (0.62%)

18:14
08/23/17
08/23
18:14
08/23/17
18:14
Periodicals
VW to launch two-tone compact SUV, Bloomberg says »

Volkswagen plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.71

0.06 (0.56%)

18:01
08/23/17
08/23
18:01
08/23/17
18:01
Hot Stocks
Ford names Jason Luo as chairman, CEO of Ford China »

Ford announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.09

-1.66 (-0.69%)

, LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:47
08/23/17
08/23
17:47
08/23/17
17:47
Periodicals
Boeing 'disappointed' company not chosen for cruise missile deal, Bloomberg says »

Lockheed (LMT), Raytheon…

BA

Boeing

$238.09

-1.66 (-0.69%)

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

RTN

Raytheon

$178.19

-1.03 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HBM

Hudbay Minerals

$8.50

0.2 (2.41%)

17:44
08/23/17
08/23
17:44
08/23/17
17:44
Hot Stocks
Hudbay Minerals acquires 10.76M common shares of Mason Resources »

Hudbay Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

17:32
08/23/17
08/23
17:32
08/23/17
17:32
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees Q4 PC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

GES

Guess

$12.48

0.11 (0.89%)

, TLYS

Tilly's

$9.60

0.88 (10.09%)

17:29
08/23/17
08/23
17:29
08/23/17
17:29
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Guess…

GES

Guess

$12.48

0.11 (0.89%)

TLYS

Tilly's

$9.60

0.88 (10.09%)

WSM

Williams-Sonoma

$43.40

0.55 (1.28%)

PVH

PVH Corp.

$120.04

-0.28 (-0.23%)

YUME

YuMe

$5.15

0.09 (1.78%)

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

HEI

Heico

$81.11

-0.95 (-1.16%)

GBT

Global Blood Therapeutics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 07

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 28

    Sep

MATX

Matson

$24.02

0.24 (1.01%)

17:28
08/23/17
08/23
17:28
08/23/17
17:28
Hot Stocks
Matson upgrading its Honolulu terminal »

Matson announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:24
08/23/17
08/23
17:24
08/23/17
17:24
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:23
08/23/17
08/23
17:23
08/23/17
17:23
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVI

Civitas Solutions

$18.30

-0.1 (-0.54%)

17:21
08/23/17
08/23
17:21
08/23/17
17:21
Recommendations
Civitas Solutions analyst commentary  »

Civitas announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$179.28

-1.39 (-0.77%)

17:20
08/23/17
08/23
17:20
08/23/17
17:20
Hot Stocks
L3 Technologies awarded $172.9M government contract modification »

L-3 Communications Vertex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.08

-1.67 (-0.70%)

17:19
08/23/17
08/23
17:19
08/23/17
17:19
Hot Stocks
Boeing awarded $222.5M government contract modification »

The Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$178.19

-1.03 (-0.57%)

17:18
08/23/17
08/23
17:18
08/23/17
17:18
Hot Stocks
Raytheon awarded approximately $900M government contract »

Raytheon Co., Tucson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:17
08/23/17
08/23
17:17
08/23/17
17:17
Hot Stocks
Lockheed Martin awarded approximately $900M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

, SSNLF

Samsung

$2,020.00

-10 (-0.49%)

17:11
08/23/17
08/23
17:11
08/23/17
17:11
Hot Stocks
HP Inc. sees Samsung deal closing in Q4 »

HP Inc. (HPQ) said it saw…

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

SSNLF

Samsung

$2,020.00

-10 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.